A research study conducted proteomics analysis of CSF from healthy controls, Parkinson’s disease (PD) patients with and without the LRRK2 G2019S mutation, and individuals with non-manifesting LRRK2 G2019S. This evidence concerns the gene LRRK2 and Parkinson disease.